Clovis Oncology (CLVS)

Clovis Oncology (CLVS) Stock Price & Analysis


CLVS Stock Chart & Stats

Day’s Range$0.08 - $0.0977
52-Week Range― - ―
Previous Close$0.09
Average Volume (3M)N/A
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
Shares Outstanding144,955,263
10 Day Avg. Volume15,445,470
30 Day Avg. Volume8,008,881
Standard Deviation0.58
Financial Highlights & Ratios
Price to Book (P/B)-0.02
Price to Sales (P/S)0.09
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Sell
Number of Analyst Covering1



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Clovis Oncology’s price range in the past 12 months?
Currently, no data Available
What is Clovis Oncology’s market cap?
Currently, no data Available
When is Clovis Oncology’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Clovis Oncology’s earnings last quarter?
Currently, no data Available
Is Clovis Oncology overvalued?
According to Wall Street analysts Clovis Oncology’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
    Does Clovis Oncology pay dividends?
    Clovis Oncology does not currently pay dividends.
    What is Clovis Oncology’s EPS estimate?
    Clovis Oncology’s EPS estimate for its next earnings report is not yet available.
    How many shares outstanding does Clovis Oncology have?
    Currently, no data Available
    What happened to Clovis Oncology’s price movement after its last earnings report?
    Currently, no data Available
    Which hedge fund is a major shareholder of Clovis Oncology?
    Among the largest hedge funds holding Clovis Oncology’s share is Gamco Investors, Inc. ET AL. It holds Clovis Oncology’s shares valued at 173K.


      Clovis Oncology Stock Smart Score

      This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
      Learn more about TipRanks Smart Score

      Company Description

      Clovis Oncology

      Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.


      Forecast EPS vs Actual EPS

      Currently, no data available
      Please return soon. This page is being updated.

      Similar Stocks
      Price & Change
      Galera Therapeutics
      MEI Pharma
      SAB Biotherapeutics
      Akebia Therapeutics
      Applied Therapeutics

      Popular Stocks

      What's Included in PREMIUM?
      Make informed decisions based on Top Analysts' activity
      Know what industry insiders are buying
      Get actionable alerts from top Wall Street Analysts
      Find out before anyone else which stock is going to shoot up
      Get powerful stock screeners & detailed portfolio analysis